フルテキストファイル
著者
小山 哲史 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧
藤原 和典 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧 KAKEN
Morisaki, Tsuyoshi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine
三宅 成智 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧 KAKEN
福原 隆宏 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧 KAKEN
竹内 裕美 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧 KAKEN
キーワード
Recurrent and metastatic
Head and neck cancer
Second-line
Successive
Chemotherapy
抄録
ObjectiveThe increase in treatment options resulted in successful treatment with multiple lines of chemotherapy for recurrent and metastatic (RM) head and neck cancer (HNC). The present study aimed to elucidate the beneficial effect of successive treatment for RM-HNC. MethodsWe included 78 patients with RM-HNC who received one or multiple lines of chemotherapy from January 2008 to December 2019. We divided the patients into three groups according to treatment period: January 2008 to November 2012 included those who underwent cancer chemotherapy only with cytotoxic agents (Tox group), December 2012 to March 2017 included those who received cytotoxic agents and cetuximab (Cet group), and March 2017 to December 2019 included those who received cytotoxic agents, cetuximab and immune checkpoint inhibitor nivolumab (Nivo group). Moreover, we compared the overall survival of the three groups. ResultsIn total, 18, 33, and 27 patients were included in the Tox, Cet, and Nivo groups, respectively. The median overall survival were 8.5 months in the Tox group, 16 months in the Cet group, and 19 months in the Nivo group, and the difference in the result was significant. ConclusionsSuccessive treatment with second and subsequent lines of chemotherapy in patients with RM-HNC improves prognosis.
出版者
Elsevier B.V.
資料タイプ
学術雑誌論文
外部リンク
ISSN
03858146
掲載誌名
Auris Nasus Larynx
最新掲載誌名
Auris Nasus Larynx
48
1
開始ページ
161
終了ページ
165
発行日
2021-02
出版者DOI
著者版フラグ
著者版
著作権表記
© 2020 Oto-Rhino-Laryngological Society of Japan Inc. Published by Elsevier B.V. All rights reserved.
掲載情報
Koyama, Satoshi. Fujiwara, Kazunori. Morisaki, Tsuyoshi. et al. Efficacy of second and subsequent lines of chemotherapy for recurrent and metastatic head and neck cancer. Auris Nasus Larynx. 2021. 48(1), 161-165.
部局名
医学部・医学系研究科・医学部附属病院
言語
英語
pii
S0385-8146(20)30197-8